More on Myb in myelofibrosis: Molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders [4]

Blood

Volumn 107, Issue 4, 2006, Pages 1733-1734

  Steensma, David P ^a   Pardanani, Animesh ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; GENOMIC DNA; PROTEIN; PROTEIN C MYB; PROTEIN MYB; PROTEIN P300; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; EXON; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GRANULOCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MUTAGENESIS; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; THROMBOCYTHEMIA;

EID: 32644432688     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3646     Document Type: Letter

References (16)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
3. Kralovics R, Passamonti F, Buser A, et al. A gain-of-function mutation of Jak2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell. 2005;7:387-397.
5. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005;80:947-958.
6. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
7. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
8. Carpinelli MR, Hilton DJ, Metcalf D, et al. Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc Natl Acad Sci U S A. 2004;101:6553-6558.
9. Metcalf D, Carpinelli MR, Hyland C, et al. Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. Blood. 2005;105:3480-3487.
10. Kasper LH, Boussouar F, Ney PA, et al. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature. 2002;419:738-743.
11. Mucenski ML, McLain K, Kier AB, et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 1991;65:677-689.
12. Frampton J, McNagny K, Sieweke M, Philip A, Smith G, Graf T. v-Myb DNA binding is required to block thrombocytic differentiation of Myb-Ets-transformed multipotent haematopoietic progenitors. EMBO J. 1995;14:2866-2875.
13. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88:402-409.
14. Vannucchi AM, Bianchi L, Paoletti F, Di Giacomo V, Migliaccio G, Migliaccio AR. Impaired GATA-1 expression and myelofibrosis in an animal model. Pathol Biol (Paris). 2004;52:275-279.
15. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002;100:1123-1132.
16. Slamon DJ, Boone TC, Murdock DC, et al. Studies of the human c-myb gene and its product in human acute leukemias. Science. 1986;233:347-351.